Home > Meet us > HARMONY Alliance will participate in MDS2021

HARMONY Alliance will participate in MDS2021

Virtual

September 23, 2021 08:00 - September 26, 2021 - 18:00

The HARMONY Alliance will participate in the 16th International Congress on Myelodysplastic Syndromes taking place at 23-26 September, 2021, organized by the MDS Foundation and the Canadian Local Organizing Committee. Due to the pandemic and it's implications, the organization decided to transform MDS 2021 into a fully Virtual Congress.

The MDS2021 Congress will cover the most recent discoveries in MDS basic and translational research as well as all relevant clinical aspects of MDS diagnosis, prognosis, and management. The main lectures will be delivered by recognized international leaders in the field, and we look forward to including high-level research presentations, selected from the abstracts submitted by colleagues.

Click here to visit the congress website  >


More information about the HARMONY participation to follow

In the mean time read more about: HARMONY and MDS >


#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies

The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on various Hematologic Malignancies. The HARMONY Alliance, funded by Innovative Medicines Initiative, unites more than 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. The aim is to accelerate the development of more effective treatments. Data are stored in HARMONY’s Big Data Platform, which has already identified over 70,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods. 


Receive the latest news. Click here to subscribe!